LOWELL, Mass., March 15, 2016 -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the addition of Natale (Nat) Ricciardi to its Board of Directors.
Mr. Ricciardi spent his entire 39-year career at Pfizer Inc, retiring in 2011. At retirement Nat held the positions of President, Pfizer Global Manufacturing and Senior Vice President, Pfizer Inc. In addition to his corporate leadership role, Nat was directly responsible for all of Pfizer’s internal and external supply organization – a global enterprise with as many as 38,000 employees and more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. He played a leadership role in shaping a mission-driven and values-based culture as the company went through phases of growth, mergers and acquisitions and transformation. His relentless focus on Quality and Compliance became a competitive advantage. His passion for science and technology and for creating a culture of continuous improvement, as drivers of efficient and effective processes, were felt across Pfizer and delivered billions of dollars in cost savings as the business transformed.
“We are delighted to welcome Nat to the Board of Directors. He brings a wealth of experience in global manufacturing and quality operations in our target industries and will be a key advisor to Rapid Micro Biosystems as we continue to execute our vision of automating microbial quality control throughout the pharmaceutical, biotech, personal care and medical device industries,” said Robert Spignesi, Chief Executive Officer.
Mr. Ricciardi earned a degree in Chemical Engineering from the City College of New York (CCNY) and an M.B.A. in Finance and International Business from Fordham University. He serves on the Board of Directors of Dynavax Technologies, Inc., Asterias Biotherapeutics, Inc. and is on the Strategic Advisory Board of HealthCare Royalty Partners. He is currently a member of the Board of the 21st Century Foundation of CCNY.
“I am excited to join the Board of Directors of Rapid Micro Biosystems at a time when this company is making a significant impact in the pharmaceutical and biotechnology industries with new and innovative approaches to automated, rapid microbiological detection methods,” said Nat Ricciardi. “I look forward to contributing my experience in leading global manufacturing and quality operations to the Company’s success.”
About Rapid Micro Biosystems:
Rapid Micro Biosystems delivers the Growth Direct™ System, an automated, non-destructive rapid detection and enumeration technology based on the compendial method for microbial quality control in pharmaceutical manufacturing. The system automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis. The detection technology, first developed and patented by Dr. Don Straus, Ph.D., uses the natural auto-fluorescence of microbes and requires no reagents. For more information about Rapid Micro Biosystems visit www.rapidmicrobio.com
Contact: Eugenia Kendrick Rapid Micro Biosystems [email protected]


Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 



